Multidimensional MR spectroscopic imaging of prostate cancer in vivo

NMR in Biomedicine

Volumn 27, Issue 1, 2014, Pages 53-66

  Thomas, M Albert ^a   Nagarajan, Rajakumar ^a   Huda, Amir ^a,b   Margolis, Daniel ^a   Sarma, Manoj K ^a   Sheng, Ke ^c   Reiter, Robert E ^c   Raman, Steven S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CALIFORNIA STATE UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

2D JPRESS; 2D L COSY; Citrate; Echo planar spectroscopic imaging; Magnetic resonance spectroscopy; Prostate cancer; Spermine

Indexed keywords

2D JPRESS; 2D L-COSY; CITRATE; ECHO-PLANAR SPECTROSCOPIC IMAGING; PROSTATE CANCERS; SPERMINE;

AMINO ACIDS; ENCODING (SYMBOLS); MAGNETIC RESONANCE SPECTROSCOPY; THREE DIMENSIONAL; TRANSPLANTS; UROLOGY;

DISEASES;

ARTICLE; CORRELATED SPECTROSCOPY; ECHO PLANAR IMAGING; HUMAN; INFORMATION PROCESSING; J RESOLVED SPECTROSCOPY; NUCLEAR MAGNETIC RESONANCE SCANNER; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROSTATE CANCER; SPECTROSCOPY; THREE DIMENSIONAL IMAGING;

2D JPRESS; 2D L-COSY; CITRATE; ECHO-PLANAR SPECTROSCOPIC IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; PROSTATE CANCER; SPERMINE;

DIAGNOSTIC IMAGING; ECHO-PLANAR IMAGING; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; METABOLOME; PROSTATE; PROSTATIC NEOPLASMS;

EID: 84890884590     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.2991     Document Type: Article

References (110)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 2010; 60(5): 277-300.
2. Gerber GS, Chodak GW. Routine screening for cancer of the prostate. J. Natl. Cancer Inst. 1991; 83(5): 329-335.
3. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J. Urol. 1974; 111(1): 58-64.
4. Amin M, Boccon-Gibod L, Egevad L, Epstein JI, Humphrey PA, Mikuz G, Newling D, Nilsson S, Sakr W, Srigley JR, Wheeler TM, Montironi R. Prognostic and predictive factors and reporting of prostate carcinoma in prostate needle biopsy specimens. Scand. J. Urol. Nephrol. 2005; 216: 20-33.
5. Carvalhal GF, Smith DS, Mager DE, Catalona WJ. Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4ng/mL or less. J. Urol. 1999; 161(3): 835-839.
6. Eastham JA, May R, Robertson JL, Sartor O, Kattan MW. Development of a nomogram that predicts the probability of a positive prostate biopsy in men with an abnormal digital rectal examination and a prostate-specific antigen between 0 and 4ng/mL. Urology 1999; 54(4): 708-713.
7. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, Waters WB, MacFarlane MT, Southwick PC. Comparison of digital rectal examination and serum prostate specific antigen (PSA) in the early detection of prostate cancer: results of a multicentre clinical trial of 6, 630 men. J. Urol. 1994; 151(5): 1283-1290.
8. Schröder FH, van der Maas P, Beemsterboer P, Kruger AB, Hoedemaeker R, Rietbergen J, Kranse R. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. J. Natl. Cancer Inst. 1998; 90(23): 1817-1823.
9. Schröder FH, Carter HB, Wolters T, van den Bergh RC, Gosselaar C, Bangma CH, Roobol MJ. Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics. Eur. Urol. 2008; 53(3): 468-477.
10. Kurhanewicz J, Vigneron D, Carroll P, Coakley F. Multiparametric magnetic resonance imaging in prostate cancer: present and future. Curr. Opin. Urol. 2008; 18(1): 71-77.
11. Kurhanewicz J, Swanson MG, Nelson SJ, Vigneron DB. Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer. J. Magn. Reson. Imaging 2002; 16(4): 451-463.
12. Schiebler ML, Tomaszewski JE, Bezzi M, Pollack HM, Kressel HY, Cohen EK, Altman HG, Gefter WB, Wein AJ, Axel L. Prostatic carcinoma and benign prostatic hyperplasia: correlation of high-resolution MR and histopathologic findings. Radiology 1989; 172: 131-137.
13. Berman CG, Brodsky NJ. Prostate cancer imaging. Cancer Control 1998; 5: 541-554.
14. Beyersdorff D, Taupitz M, Winkelmann B, Fischer T, Lenk S, Loening SA, Hamm B. Patients with a history of elevated prostate-specific antigen levels and negative transrectal US-guided quadrant or sextant biopsy results: value of MR imaging. Radiology 2002; 224: 701-706.
15. Le Bihan D, Breton E, Lallemand D, Aubin ML, Vignaud J, Laval-Jeantet M. Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology 1988; 168: 497-505.
16. Miao H, Fukatsu H, Ishigaki T. Prostate cancer detection with 3-T MRI: comparison of diffusion-weighted and T2-weighted imaging. Eur. J. Radiol. 2007; 61: 297-302.
17. Lim HK, Kim JK, Kim KA, Cho KS. Prostate cancer: apparent diffusion coefficient map with T2-weighted images for detection - a multireader study. Radiology 2009; 250: 145-151.
18. Mazaheri Y, Hricak H, Fine SW, Akin O, Shukla-Dave A, Ishill NM, Moskowitz CS, Grater JE, Reuter VE, Zakian KL, Touijer KA, Koutcher JA. Prostate tumor volume measurement with combined T2-weighted imaging and diffusion weighted MR: correlation with pathologic tumor volume. Radiology 2009; 252: 449-457.
19. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-257.
20. Padhani AR, Husband JE. Dynamic contrast-enhanced MRI studies in oncology with an emphasis on quantification, validation and human studies. Clin. Radiol. 2001; 56: 607-620.
21. Bigler SA, Deering RE, Brawer MK. Comparison of microscopic vascularity in benign and malignant prostate tissue. Hum. Pathol. 1993; 24: 220-226.
22. Kiessling F, Lichy M, Grobholz R, Heilmann M, Farhan N, Michel MS, Trojan L, Ederle J, Abel U, Kauczor HU, Semmler W, Delorme S. Simple models improve the discrimination of prostate cancers from the peripheral gland by T1-weighted dynamic MRI. Eur. Radiol. 2004; 14: 1793-1801.
23. Mydlo JH, Kral JG, Volpe M, Axotis C, Macchia RJ, Pertschuk LP. An analysis of microvessel density, androgen receptor, p53 and HER-2/neu expression and Gleason score in prostate cancer: preliminary results and therapeutic implications. Eur. Urol. 1998; 34: 426-432.
24. Schlemmer HP, Merkle J, Grobholz R, Jaeger T, Michel MS, Werner A, Rabe J, van Kaick G. Can pre-operative contrast-enhanced dynamic MR imaging for prostate cancer predict microvessel density in prostatectomy specimens? Eur. Radiol. 2004; 14: 309-317.
25. Jager GJ, Ruijter ET, van de Kaa CA, de la Rosette JJ, Oosterhof GO, Thornbury JR, Ruijs SH, Barentsz JO. Dynamic TurboFLASH subtraction technique for contrast-enhanced MR imaging of the prostate: correlation with histopathologic results. Radiology 1997; 203: 645-652.
26. Preziosi P, Orlacchio A, Di Giambattista G, Di Renzi P, Bortolotti L, Fabiano A, Cruciani E, Pasqualetti P. Enhancement patterns of prostate cancer in dynamic MRI. Eur. Radiol. 2003; 13: 925-930.
27. Rouviere O, Raudrant A, Ecochard R, Colin-Pangaud C, Pasquiou C, Bouvier R, Maréchal JM, Lyonnet D. Characterization of time-enhancement curves of benign and malignant prostate tissue at dynamic MR imaging. Eur. Radiol. 2003; 13: 931-942.
28. Engelbrecht MR, Huisman HJ, Laheij RJ, Jager GJ, van Leenders GJ, Hulsbergen-Van De Kaa CA, de la Rosette JJ, Blickman JG, Barentsz JO. Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. Radiology 2003; 229: 248-254.
29. McMahon CJ, Bloch BN, Lenkinski RE, Rofsky NM. Dynamic contrast-enhanced MR imaging in the evaluation of patients with prostate cancer. Magn. Reson. Imaging Clin. N. Am. 2009; 17: 363-383.
30. Bonekamp D, Macura KJ. Dynamic contrast-enhanced magnetic resonance imaging in the evaluation of the prostate. Top. Magn. Reson. Imaging 2008; 19; 273-284.
31. Macura KJ. Multiparametric magnetic resonance imaging of the prostate: current status in prostate cancer detection, localization, and staging. Semin. Roentgenol. 2008; 43: 303-313.
32. Futterer JJ, Heijmink SW, Scheenen TW, Veltman J, Huisman HJ, Vos P, Hulsbergen-Van de Kaa CA, Witjes JA, Krabbe PF, Heerschap A, Barentsz JO. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology 2006; 241: 449-458.
33. Ocak I, Bernardo M, Metzger G, Barrett T, Pinto P, Albert PS, Choyke PL. Dynamic contrast-enhanced MRI of prostate cancer at 3T: a study of pharmacokinetic parameters. Am. J. Roentgenol. 2007; 189: 849.
34. Kim JK, Hong SS, Choi YJ, Park SH, Ahn H, Kim CS, Cho KS. Wash-in rate on the basis of dynamic contrast-enhanced MRI: usefulness for prostate cancer detection and localization. J. Magn. Reson. Imaging 2005; 22: 639-646.
35. Kim CK, Park BK, Kim B. Localization of prostate cancer using 3T MRI - comparison of T2-weighted and dynamic contrast-enhanced imaging. J. Comput. Assist. Tomogr. 2006; 30: 7-11.
36. Engelbrecht MR, Huisman HJ, Laheij RJ, Jager GJ, van Leenders GJ, Hulsbergen-Van De Kaa CA, de la Rosette JJ, Blickman JG, Barentsz JO. Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. Radiology 2003; 229: 248-254.
37. Ren J, Huan Y, Wang H, Chang YJ, Zhao HT, Ge YL, Liu Y, Yang Y. Dynamic contrast-enhanced MRI of benign prostatic hyperplasia and prostatic carcinoma: correlation with angiogenesis. Clin. Radiol. 2008; 63: 153-159.
38. Padhani AR, Gapinski CJ, Macvicar DA, Parker GJ, Suckling J, Revell PB, Leach MO, Dearnaley DP, Husband JE. Dynamic contrast enhanced MRI of prostate cancer: correlation with morphology and tumour stage, histological grade and PSA. Clin. Radiol. 2000; 55: 99-109.
39. Thomas MA, Narayan P, Kurhanewicz J, Jajodia P, Weiner MW. 1HMR spectroscopy of normal and malignant human prostates in vivo. J. Magn. Reson. 1990; 87: 610-619.
40. Kurhanewicz J, Vigneron DB, Nelson SJ, Hricak H, MacDonald JM, Konety B, Narayan P. Citrate as an in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone: detection via localized proton spectroscopy. Urology 1995; 3: 459-466.
41. Govindaraju V, Young K, Maudsley AA. Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed. 2000; 13(3): 129-153.
42. Nagarajan R, Margolis D, Raman S, Sarma MK, Sheng K, King CR, Verma G, Sayre J, Reiter RE, Thomas MA. MR spectroscopic imaging and diffusion-weighted imaging of prostate cancer with Gleason scores. J. Magn. Reson. Imaging 2012; 36(3): 697-703.
43. Petroff OA, Rothman DL, Behar KL, Mattson RH. Initial observations on effect of vigabatrin on in vivo 1H spectroscopic measurements of gamma-aminobutyric acid, glutamate, and glutamine in human brain. Epilepsia 1995; 36(5): 457-464.
44. Trabesinger AH, Meier D, Boesiger P. In vivo 1H NMR spectroscopy of individual human brain metabolites at moderate field strengths. Magn. Reson. Imaging 2003; 21: 1295-1302.
45. Keltner JR, Wald LL, Christensen JD, Maas LC, Moore CM, Cohen BM, Renshaw PF. A technique for detecting GABA in the human brain with PRESS localization and optimized refocusing spectral editing radiofrequency pulses. Magn. Reson. Med. 1996; 36: 458-461.
46. Rothman DI, Petroff OA, Behar KL, Mattson RH. Localized 1H NMR measurements of γ-aminobutyric acid in human brain in vivo. Proc. Natl Acad. Sci. USA 1993; 90: 5662-5666.
47. Lee HK, Yaman A, Nalcioglu O. Homonuclear J-refocused spectral editing technique for quantification of glutamine and glutamate by 1H NMR spectroscopy. Magn. Reson. Med. 1995; 34: 253-259.
48. Aue WP, Bartholdi E, Ernst RR. Two-dimensional spectroscopy - application to nuclear magnetic resonance. J. Chem. Phys. 1976; 64(5): 2229-2246.
49. Ryner LN, Sorenson JA, Thomas MA. 3-D localized 2D-NMR spectroscopy on an MRI scanner. J. Magn. Reson. B 1995; 107: 126-137.
50. Ryner LN, Sorenson JA, Thomas MA. Localized 2D J-resolved H-1 MR spectroscopy: strong coupling effects in vitro and in vivo. Magn. Reson. Imaging 1995; 13: 853-869.
51. Kreis R, Boesch C. Spatially localized, one- and two-dimensional NMR spectroscopy and in vivo application to human muscle. J. Magn. Reson. 1996; B113: 103-118.
52. Thomas MA, Yue K, Binesh N, Davanzo P, Kumar A, Siegel B, Frye M, Curran J, Lufkin R, Martin P, Guze B. Localized two dimensional shift correlated MR spectroscopy of human brain. Magn. Reson. Med. 2001; 46: 58-67.
53. Swanson MG, Vigneron DB, Tran TK, Sailasuta N, Hurd RE, Kurhanewicz J. Single-voxel oversampled J-resolved spectroscopy of in vivo human prostate tissue. Magn. Reson. Med. 2001; 45(6): 973-980.
54. Yue K, Marumoto A, Binesh N, Thomas MA. 2D JPRESS of human prostates using an endorectal receiver coil. Magn. Reson. Med. 2002; 47(6): 1059-1064.
55. 1H MR spectroscopy of human prostates using an endorectal coil. Spectroscopy 2003; 17(2/3): 521-527.
56. Nagarajan R, Gomez AM, Raman SS, Margolis DJ, McClure T, Thomas MA. Correlation of endorectal 2D JPRESS findings with pathological Gleason scores in prostate cancer patients. NMR Biomed. 2010; 23(3): 257-261.
57. Ernst RR, Bodenhausen G, Wokaun A. Principles of NMR Spectroscopy in One and Two Dimensions. Oxford University Press: Oxford; 1987, pp. 283-533.
58. Levitt MH. Spin Dynamics: Basics of Nuclear Magnetic Resonance. Wiley: Chichester, UK; 2002, pp. 361-383.
59. Keeler J. Understanding NMR Spectroscopy. Wiley: Cambridge; 2002.
60. Ziegler A, Izquierdo M, Remy C, Decorps M. Optimization of homonuclear two-dimensional correlation methods for in vivo and ex vivo NMR. J. Magn. Reson. 1995; B107: 10-18.
61. Kumar A. Two-dimensional spin-echo NMR spectroscopy: a general method for calculation of spectra. J. Magn. Reson. 1978; 30: 227-249.
62. Delikatny EJ, Hull WE, Mountford CE. The effect of altering time domains and window functions in two-dimensional proton COSY spectra of biological specimens. J. Magn. Reson. 1991; 94: 563-573.
63. Thrippleton MJ, Edden RAE, Keeler J. Suppression of strong coupling artefacts in J-spectra. J. Magn. Reson. 2005; 174: 97-109.
64. Smith SA, Levante TO, Meier BH, Ernst RR. Computer simulations in magnetic resonance. An object-oriented programming approach. J. Magn. Reson. 1994; 106A: 75-105.
65. Cheng LL, Wu C, Smith MR, Gonzalez RG. Non-destructive quantitation of spermine in human prostate tissue samples using HRMAS 1H NMR spectroscopy at 9.4T. FEBS Lett. 2001; 494: 112-116.
66. Serkova NJ, Gamito EJ, Jones RH, O'Donnell C, Brown JL, Green S, Sullivan H, Hedlund T, Crawford ED. The metabolites citrate, myo-inositol, and spermine are potential age-independent markers of prostate cancer in human expressed prostatic secretions. Prostate 2008; 68: 620-628.
67. Van der Graaf M, Schipper RG, Oosterhof GO, Schalken JA, Verhofstad AA, Heerschap A. Proton MR spectroscopy of prostatic tissue focused on the detection of spermine, a possible biomarker of malignant behavior in prostate cancer. Magn. Reson. Mater. Phys. Biol. Med. 2000; 10: 153-159.
68. Mi Z, Kramer DL, Miller JT, Bergeron RJ, Bernacki R, Porter CW. Human prostatic carcinoma cell lines display altered regulation of polyamine transport in response to polyamine analogs and inhibitors. Prostate 1998; 34: 51-60.
69. Lange T, Schulte RF, Boesiger P. Quantitative J-resolved prostate spectroscopy using two-dimensional prior-knowledge fitting. Magn. Reson. Med. 2008; 59(5): 966-972.
70. Baker EH, Basso G, Barker PB, Smith MA, Bonekamp D, Horská A. Regional apparent metabolite concentrations in young adult brain measured by (1)H MR spectroscopy at 3 Tesla. J. Magn. Reson. Imaging 2008; 27(3): 489-499.
71. Mlyanarik V, Gruber S, Moser E. Proton T(1) and T(2) relaxation times of human brain metabolites at 3 Tesla. NMR Biomed. 2001; 5: 325-331.
72. Schulte RF, Lange T, Beck J, Meier D, Boesiger P. Improved two-dimensional J-resolved spectroscopy. NMR Biomed. 2006; 19: 264-270.
73. Mansfield P. Spatial mapping of the chemical shift in NMR. Magn. Reson. Med. 1984; 1: 370-386.
74. Matsui S, Sekihara K, Kohno H. High speed spatially resolved NMR spectroscopy using phase modulated spin echo trains. Expansion of the spectral bandwidth by combined use of delayed spin echo trains. J. Magn. Reson. 1985; 64: 167-171.
75. Posse S, Tedeschi G, Risinger R, Ogg R, Bihan DL. High speed 1H spectroscopic imaging in human brain by echo planar spatial-spectral encoding. Magn. Reson. Med. 1995; 33: 34-40.
76. Ebel A, Soher BJ, Maudsley AA. Assessment of 3D proton MR echo-planar spectroscopic imaging using automated spectral analysis. Magn. Reson. Med. 2001; 46: 1072-1078.
77. Mulkern RV, Panych LP. Echo planar spectroscopic imaging. Concepts Magn. Reson. 2001; 13: 213-237.
78. Du W, Du YP, Fan X, Zamora MA, Karczmar GS. Reduction of spectral ghost artifacts in high-resolution echo-planar spectroscopic imaging of water and fat resonances. Magn. Reson. Med. 2003; 49(6): 1113-1120.
79. Chen AP, Cunningham CH, Ozturk-Isik E, Xu D, Hurd RE, Kelley DA, Pauly JM, Kurhanewicz J, Nelson SJ, Vigneron DB. High speed 3T MR spectroscopic imaging of prostate with flyback echo-planar encoding. J. Magn. Reson. Imaging 2007; 25: 1288-1292.
80. Du W, Fan X, Foxley S, Zamora M, River JN, Culp RM, Karczmar GS. Comparison of high resolution echo-planar spectroscopic imaging with conventional MR imaging of prostate tumors in mice. NMR Biomed. 2005; 18: 285-292.
81. Lipnick S, Verma G, Ramadan S, Furuyama J, Thomas MA. Echo planar correlated spectroscopic imaging: implementation and pilot evaluation in human calf in vivo. Magn. Reson. Med. 2010; 64: 947-956.
82. Nagarajan R, Furuyama J, Margolis D, Raman S, Sarma M, Thomas M. Echo planar based J resolved and correlated spectroscopic imaging of human prostate using external coil. In: Proceedings of the ISMRM, Montreal, Canada, 2011. p. 2801.
83. Hennig J, Nauerth A, Friedburg H. RARE imaging: a fast imaging method for clinical MR. Magn. Reson. Med. 1986; 3: 823-833.
84. Constable R, Smith R, Gore J. Signal-to-noise and contrast in fast spin echo (FSE) and inversion recovery FSE imaging. J. Comput. Assist. Tomogr. 1992; 16(1): 41-47.
85. Listerud J, Einstein S, Outwater E, Kressel HY. First principles of fast spin echo. Magn. Reson. Q. 1992; 8(4): 199-244.
86. Duyn JH, Moonen CTW. Fast proton spectroscopic imaging of human brain using multiple spin-echoes. Magn. Reson. Med. 1993; 30: 409-414.
87. Dydak U, Meier D, Lamerichs R, Boesiger P. Trading spectral separation at 3T for acquisition speed in multi spin-echo spectroscopic imaging. Am. J. Neruroradiol. 2006; 27: 1441-1446.
88. Rutgers DR, van der Grond J. Relaxation times of choline, creatine and N-acetyl aspartate in human cerebral white matter at 1.5T. NMR Biomed. 2002; 3: 215-221.
89. Nagarajan R, Furuyama J, Sarma MK, Margolis D, Raman S, Reiter RE. Multi-echo EP-based J-resolved magnetic resonance spectroscopic imaging of prostate cancer. In: RSNA-Scientific Meeting 2011 (Chicago, USA). Abstract 186.
90. Donoho D. Compressed sensing. IEEE Trans. Info. Theory 2006; 52: 1289-1306.
91. Candez EJ, Romberg J, Tao T. Stable signal recovery from incomplete and inaccurate measurements. Commun. Pure Appl. Math. 2006; 59: 1207-1221.
92. Lustig M, Donoho D, Pauly JM. Sparse MRI: the application of compressed sensing for rapid MR imaging. Magn. Reson. Med. 2007; 58(6): 1182-1195.
93. Doneva M, Börnert P, Eggers H, Mertins A, Pauly J, Lustig M. Compressed sensing for chemical shift-based water-fat separation. Magn. Reson. Med. 2010; 64(6): 1749-1759.
94. Hu S, Lustig M, Chen AP, Crane J, Kerr A, Kelley DA, Hurd R, Kurhanewicz J, Nelson SJ, Pauly JM, Vigneron DB. Compressed sensing for resolution enhancement of hyperpolarized 13C flyback 3D-MRSI. J. Magn. Reson. 2008; 192(2): 258-264.
95. Gamper U, Boesiger P, Kozerke S. Compressed sensing in dynamic MRI. Magn. Reson. Med. 2008; 59: 365-373.
96. Michailovich O, Rathi Y, Dolui S. Spatially regularized compressed sensing for high angular resolution diffusion imaging. IEEE Trans. Med. Imaging 2011; 30: 1100-1115.
97. Wu B, Millane RP, Watts R, Bones PJ. Prior estimate based compressed sensing in parallel MRI. Magn. Reson. Med. 2011; 65: 83-95.
98. Hu S, Lustig M, Balakrishnan A, Larson PE, Bok R, Kurhanewicz J, Nelson SJ, Goga A, Pauly JM, Vigneron DB. 3D compressed sensing for highly accelerated hyperpolarized 13C MRSI with in vivo applications to transgenic mouse models of cancer. Magn. Reson. Med. 2010; 63: 312-321.
99. Scheenen TW, Heijmink SW, Roell SA, Hulsbergen-Van de Kaa CA, Knipscheer BC, Witjes JA, Barentsz JO, Heerschap A. Three-dimensional proton MR spectroscopy of human prostate at 3T without endorectal coil: feasibility. Radiology 2007; 245: 507-516.
100. Kim DH, Margolis D, Xing L, Daniel B, Spielman D. In vivo prostate magnetic resonance spectroscopic imaging using two-dimensional J-resolved PRESS at 3T. Magn. Reson. Med. 2005; 53(5): 1177-1182.
101. Goldstein T, Osher S. The split Bregman method for L1-regularized problems. SIAM Journal on Imaging Sciences 2009; 2(2): 323-343.
102. Furuyama J, Wilson N, Burns B, Nagarajan R, Margolis D, Thomas MA. Application of compressed sensing to multidimensional spectroscopic imaging in human prostate. Magn. Reson. Med. 2012; 67: 1499-1505.
103. DeFeo EM, Cheng LL. Characterizing human cancer metabolomics with ex vivo 1H HRMAS MRS. Technol. Cancer Res. Treat. 2010; 9: 381-391.
104. Stenman K, Stattin P, Stenlund H, Riklund K, Gröbner G, Bergh A. 1H HRMAS NMR derived biomarkers related tumor grade, tumor cell fraction, and cell proliferation in prostate tissue samples. Biomarker Insights 2011; 6: 39-47.
105. Swanson MG, Vigneron DB, Tabatabai ZL, Males RG, Schmitt L, Carroll PR, James JK, Hurd RE, Kurhanewicz J. Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI/3D-MRSI-targeted post-surgical prostate tissues. Magn. Reson. Med. 2003; 50: 944-954.
106. Wright A, Tessem MB, Bertilsson H, Grinde MT, Giskeødegård GF, Halgunset J, Angelsen A, Heerschap A, Gribbestad IS. Quantitative 1H HR-MAS using LC Model shows glutamate, choline, glycerylphosphocholine, and glucose as biomarkers of prostate. Proc. Intl Soc. Magn. Reson. Med. 2012; 20: 2975.
107. Thomas MA, Lange T, Velan SS, Nagarajan R, Raman S, Gomez A, Margolis D, Swart S, Raylman RR, Schulte RF, Boesiger P. Two-dimensional MR spectroscopy of healthy and cancerous prostates in vivo. Magn. Reson. Mater. Phys. Biol. Med. 2008; 21(6): 443-458.
108. Cavassila S, Deval S, Huegen C, van Ormondt D, Graveron-Demilly D. Cramer-Rao bound expressions for parametric estimation of overlapping peaks: influence of prior knowledge. J. Magn. Reson. 2000; 143(2): 311-320.
109. Sarma MK, Huda A, Nagarajan R, Hinkin CH, Wilson N, Gupta RK, Frias-Martinez E, Sayre J, Guze B, Han SH, Thomas MA. Multi-dimensional MR spectroscopy: towards a better understanding of hepatic encephalopathy. Metab. Brain Dis. 2011; 26(3): 173-184.
110. Nagarajan R, Sarma MK, Thames AD, Castellon SA, Hinkin CH, Thomas MA. 2D MR spectroscopy combined with prior-knowledge fitting is sensitive to HCV associated cerebral metabolic abnormalities. Int. J. Hepatol. 2012; 2012: 179365.